



## Medical Imaging in Malignant Liver Tumours Treatment Evaluation

Guest Editors:

**Prof. Dr. Luis Martí-Bonmati**

1. Grupo de Investigación  
Biomédica en Imagen, Instituto  
de Investigación Sanitaria La Fe,  
46026 Valencia, Spain  
2. Área Clínica de Imagen Médica,  
Hospital Universitario Y  
Politécnico La Fe, 46026 Valencia,  
Spain

**Dr. Daniel Pérez-Enguix**

Servicio de Radiología, Hospital  
Universitario Y Politécnico La Fe,  
46026 Valencia, Spain

Deadline for manuscript  
submissions:

**closed (30 September 2022)**

### Message from the Guest Editors

Dear Colleagues,

This Special Issue will address the role of medical imaging, radiomics and deep learning (DL) in malignant liver tumor (hepatocellular carcinoma, cholangiocarcinoma and hepatic metastases) treatment allocation, treatment response prediction and time-to-event estimations. The role of current guidelines, radiomic features and DL tools will be explored in work ranging from pilot studies to evidence-based knowledge reports, with an emphasis on ablative techniques, trans-arterial chemoembolization (TACE) and trans-arterial radioembolization (TARE) therapies. New interventional procedures for malignant liver tumors will be explored. The relevance of the radiological report when evaluating the effects of these treatments will be discussed. Finally, the real-world data (RWD) approach to generating real-world evidence (RWE) will also be discussed and critically approached.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)